A New Generation of Weight-Loss Drugs
A class of drugs known as GLP-1 receptor agonists, including brands like Wegovy (semaglutide), has gained significant attention for its effectiveness in weight management. These medications, often administered via injection, work by mimicking a gut hormone
that signals fullness to the brain, reduces appetite, and slows digestion. Initially developed for adults with type 2 diabetes, their powerful weight-loss effects have led to approvals for treating obesity, including in adolescents aged 12 and older. The results can be significant; one major trial showed teens losing an average of 16% of their body weight. This has positioned them as a potentially transformative tool in medicine.
The WHO's Cautious Stance
In its first-ever global guidelines on childhood obesity management, the World Health Organization has made its position clear: these drugs are not the starting point. The WHO strongly recommends that for children and adolescents, the foundation of care must be comprehensive support for healthy eating, physical activity, and sustainable behavioural changes. For children under 10, the WHO does not recommend pharmacological treatments at all. For adolescents aged 10-19, medications should only be considered if a supervised, multi-faceted lifestyle program fails to produce the desired results. This 'lifestyle-first' approach is a deliberate and crucial distinction.
Why Caution is the First Prescription
The WHO's caution stems from several key concerns. Firstly, there is a lack of long-term data on how these powerful drugs affect a teenager's growing body over many years, or even decades. Potential side effects in teens can include nausea, vomiting, and abdominal discomfort, and there are unanswered questions about impacts on bone development and mood. Furthermore, obesity is a chronic condition, and evidence suggests that if the medication is stopped, the weight is often regained. This raises the prospect of lifelong dependency starting in adolescence. The focus, experts argue, should be on addressing the root causes of obesity rather than just medicating the symptom.
What is the First-Line Treatment?
So, if not drugs, what comes first? The WHO advocates for a holistic and person-centred approach. This involves structured, intensive interventions focused on nutrition, physical activity, and behavioural therapy. It's not simply telling a teen to 'eat less and move more'. It means creating a supportive ecosystem involving family, schools, and healthcare providers. This can include access to dietitians, mental health support to address issues like bullying or depression that can accompany obesity, and creating family habits that promote healthy eating and regular physical activity. The goal is to build sustainable skills and a healthy environment, not just rely on a weekly injection.
The Indian Context: A Looming Challenge
These global guidelines are acutely relevant for India, which now ranks second in the world for the number of children and adolescents living with overweight and obesity. Recent reports indicate over 41 million young people in India are affected, with rates rising rapidly. This trend is driven by a combination of factors, including a shift toward processed foods and more sedentary lifestyles, with one estimate suggesting 74% of Indian adolescents don't meet recommended activity levels. While GLP-1 drugs are becoming available, implementing the WHO's 'lifestyle-first' model presents its own challenges, requiring significant investment in public health infrastructure, accessible green spaces, and education for families and healthcare professionals nationwide.
